Zydus Launches Vaccine to Combat New Influenza Strain

Zydus Lifesciences Launches India’s First Quadrivalent Influenza Vaccine

Zydus Lifesciences has announced the launch of a new vaccine designed to protect against the latest strain of the influenza virus. This marks a significant milestone as the company introduces India’s first quadrivalent influenza vaccine, formulated in line with the World Health Organization’s (WHO) recommended composition.

In an official statement, the Ahmedabad-based pharmaceutical giant revealed that its Quadrivalent Inactivated Influenza vaccine, VaxiFlu-4, provides seasonal protection against four new strains of the virus.

A quadrivalent vaccine offers broader protection by covering both influenza A and influenza B strains, significantly reducing the risk of vaccine mismatch, the company explained. The vaccine has already received clearance from the Central Drug Laboratory (CDL).

Addressing a Growing Public Health Concern

Commenting on the launch, Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the importance of preventive healthcare.

"Vaccines play a crucial role in improving public health worldwide. In India, there is a strong need for affordable and high-quality vaccines to address major healthcare challenges," Patel stated.

He further highlighted that VaxiFlu-4 will support annual immunization efforts and help prevent flu outbreaks, ultimately enhancing public health protection.

Developed at Zydus’ Vaccine Technology Centre

The company developed VaxiFlu-4 at its Vaccine Technology Centre (VTC) in Ahmedabad. Given the recurring outbreaks of influenza, managing the disease has become a major public health priority.

Influenza is a highly contagious respiratory infection that spreads through airborne respiratory droplets from coughing or sneezing, as well as direct contact with infected individuals or surfaces. The virus can cause mild to severe illness, sometimes leading to hospitalization or even death—especially among high-risk groups such as young children, the elderly, and individuals with weakened immune systems or chronic health conditions.

With the launch of VaxiFlu-4, Zydus Lifesciences aims to contribute to annual immunization efforts and flu prevention strategies, ensuring better protection against seasonal influenza.